Sage Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$193M
Industry:Biotech
Founded:2010
Lead Investor(s):J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Sage Therapeutics's estimated annual revenue is currently $95.9M per year.
  • Sage Therapeutics received $575.0M in venture funding in February 2018.
  • Sage Therapeutics's estimated revenue per employee is $155,000
  • Sage Therapeutics's total funding is $193M.

Employee Data

  • Sage Therapeutics has 619 Employees.
  • Sage Therapeutics grew their employee count by -12% last year.
  • Sage Therapeutics currently has 18 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$7.1M4659%N/A
Tango Therapeut...
$9M5841%N/A
Compass Therape...
$15.8M10215%N/A
Cell Signaling ...
$75.6M488N/AN/A
Momenta Pharmac...
N/A212N/AN/A
Emulate
$14.7M95-17%N/A
ArQule
N/A90N/AN/A
Hamilton Storag...
$14.6M949%N/A
Alnylam Pharmac...
$74.9M122831%N/A
Transgenomic
N/A45N/AN/A
Missing a competitor? Contribute!?
Submit

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.

keywords:Biotechnology,Healthcare,Pharmaceuticals

619

Number of Employees

$95.9M

Revenue (est)

18

Current Jobs

-12%

Employee Growth %

$193M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Kate JurcikSenior Director Regulatory Affairs Advertising And Promotion
Kimi IguchiChief Financial Officer
Jim DohertyChief Research Officer
Jeffrey JonasCeo And Director
Stephen KanesChief Medical Officer
Brian O'DonnellAssociate Director, Brand Medical Education
Christopher GalliDirector, Analytical Development
Dan HornePrincipal Scientist
Jeff KastenSenior Director, Head Of New Product Planning
Jennifer McDanielAssociate Director, Clinical Data Management

Sage Therapeutics News

09/03/2019 - Sage Therapeutics Announces the New England Journal of ...

Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive ...

09/08/2019 - Atika Capital Management LLC Trims Stock Holdings in SAGE Therapeutics Inc (NASDAQ:SAGE)

Atika Capital Management LLC lowered its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 26.7% in the second quarter, according to ...

09/03/2019 - Stocks To Maximize Your Returns: Diamond Offshore Drilling (DO), Sage Therapeutics (SAGE)

With the previous 100-day trading volume average of 397159 shares, Sage Therapeutics (SAGE) recorded a trading volume of 364280 shares, ...

Sage Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$20.0MBARCH Venture PartnersArticle
2014-01-23$10.0MUndisclosedArticle
2014-03-14$38.0MCMultipleArticle
2015-04-15$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-22$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-11-15$345.0MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-09$575.0MUndisclosedJ.P. Morgan Securities LLCArticle

Sage Therapeutics Executive Hires

DateNameTitleReference
2011-12-02Albert J. RobichaudChief Scientific OfficerArticle
2014-05-06Thomas D. AndersonChief Commercial Strategy OfficerArticle
2017-04-25Michael CloonanChief Business OfficerArticle